Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham
R
R
D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005334:Fever / Q000209:etiology; D006801:Humans; D008081:Liposomes; D009181:Mycoses / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D009503:Neutropenia / Q000150:complications* / Q000401:mortality / Q000503:physiopathology; D010713:Phosphatidylcholines / Q000009:adverse effects / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000935:Antifungal Agents; D004338:Drug Combinations; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B